Strategic CDMO Lindy Biosciences has recently engaged Lifecore Biomedical as a CDMO to streamline formulation and scale Microglassification technology for commercial manufacturing, signaling a potential need for ongoing formulation optimization, process development, and manufacturing scalability partnerships.

Funding Momentum Recent $20M financing alongside prior funding rounds indicates investor confidence and a potential budget runway for expanding development programs, process improvements, and pilot-scale manufacturing collaborations with contract partners.

Technology Fit Core Microglassification technology enables stable protein particles for high-concentration suspensions and dry powder delivery, presenting opportunities to position as a supplier of specialized formulation services or packaging-ready drug products to companies pursuing long-term storage or novel delivery routes.

Market Readiness Development-stage company with interest in subcutaneous high-dose protein suspensions and sustained/controlled release formulations suggests sales focus on premium formulation services, analytical development, and regulatory-ready packaging solutions for injectable biologics.

Growth via Partners Historical financing activity and board growth indicate a strategy open to collaborations and strategic investors; a proactive outreach to potential co-development or equity partnerships with mid- to late-stage biotechs could accelerate market entry and scale.